First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature

First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature

Abstract Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) used in both transplantation and cancer treatment (breast, renal and neuroendocrine). In transplantation, therapeutic drug monitoring (TDM) is recommended due to the potential drug–drug interactions with chronic medications,...

Full description

Bibliographic Details
Main Authors: Eduard Fort-Casamartina, Carme Muñoz-Sanchez, Raul Francisco Rigo-Bonnin, Pamela Maria del Valle-Celiz, Núria Gonzalo-Diego, Sara Otero-Torres, Carmen Bleda-Perez, Judith Prats-Jimenez, Sandra Fontanals-Martínez
Format: Article
Language:English
Published: BMC 2023-06-01
Series:European Journal of Medical Research
Subjects:
Everolimus
Pharmaceutical care
Therapeutic drug monitoring
Pharmacokinetic
Drug–drug interaction
CYP3A4 metabolism
Online Access:https://doi.org/10.1186/s40001-023-01172-w

Internet

https://doi.org/10.1186/s40001-023-01172-w

Similar Items